Charles River Laboratories International (NYSE:CRL) Trading 6.9% Higher – Should You Buy?

Charles River Laboratories International, Inc. (NYSE:CRL) shares traded up 6.9% during mid-day trading on Wednesday . The stock traded as high as $199.83 and last traded at $199.4240. Approximately 82,970 shares were traded during mid-day trading, a decline of 91% from the average session volume of 913,393 shares. The stock had previously closed at $186.60.

Analyst Ratings Changes

Several brokerages have commented on CRL. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $185.00 to $220.00 in a report on Wednesday, June 17th. Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Finally, Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective on the stock. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $211.00.

Charles River Laboratories International Trading Up 7.1%

The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a fifty day moving average price of $175.14 and a 200 day moving average price of $182.81. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -53.04, a P/E/G ratio of 2.07 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period in the previous year, the company earned $2.34 earnings per share. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of CRL. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $26,000. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $43,000. Activest Wealth Management lifted its position in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.